Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAmylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
30.21 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
1297557
Market Cap
3728.77M

Momentum Score

…

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
28.76
Low
30.32
High
52 Week Price Range
10.83
Low
41.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Amylyx Pharmaceuticals develops treatments for neurodegenerative disease and markets Relyvrio, a combination of sodium phenylbutyrate and taurursodiol approved in the U.S. for ALS. Long-term growth may be driven by Relyvrio adoption, expansion into new markets or indications, and accumulation of real‑world and clinical evidence that could support broader use.
Key risks include dependence on a single product with debated clinical support, uncertain reimbursement and commercial adoption, regulatory or post‑approval study obligations, competition from other ALS therapies, and the need for additional capital.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
30.21
Dividend Yield
-
Revenue TTM
-0.67M
Revenue Per Share
-0.01
Gross Profit TTM
-92.45M
Debt / Equity
0.02
ROE
-74.73%
Net Debt
-220.69M
ROCE
-46.68%
Diluted EPS TTM
-1.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -144.69M -302.14M 54.30M -197.60M -87.93M
Net income -144.74M -301.74M 49.27M -198.38M -87.88M
Selling general administrative 62.89M 111.63M 178.86M 127.13M 38.93M
Selling and marketing expenses - 2.70M 9.50M - -
Gross profit -0.53M 45.22M 355.35M 19.24M 0.28M
Reconciled depreciation 0.53M 0.90M 1.09M 0.49M 0.05M
Ebit -144.69M -291.88M 38.80M -201.83M -82.74M
Ebitda -144.16M -290.98M 39.89M -201.34M -82.69M
Depreciation and amortization 0.53M 0.90M 1.09M 0.49M 0.05M
Non operating income net other - - - 3.74M -
Operating income -153.29M -314.73M 38.80M -201.34M -82.69M
Other operating expenses 153.29M 402.10M 341.98M 223.57M 82.69M
Interest expense - - - 4.29M 0.04M
Tax provision 0.05M -0.39M 5.03M 0.77M -
Interest income 9.30M 13.81M 16.16M 4.29M 0.04M
Net interest income 9.30M 13.81M 16.16M 4.29M 0.04M
Income tax expense 0.05M -0.39M 5.03M 0.77M -0.05M
Total revenue 0.00M 87.37M 380.79M 22.23M 0.28M
Total operating expenses 152.77M 359.95M 316.54M 220.58M 82.69M
Cost of revenue 0.53M 42.16M 25.44M 2.99M -
Total other income expense net 8.60M 12.60M 15.49M 3.74M -5.24M
Net income from continuing ops -144.74M -301.74M 49.27M -198.38M -87.93M
Net income applicable to common shares - - - -198.38M -87.93M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 332.64M 193.63M 517.45M 391.45M 105.61M
Other current assets 6.60M 12.48M 14.93M 10.11M 8.83M
Total liab 27.39M 28.87M 84.02M 50.85M 256.78M
Total stockholder equity 305.26M 164.76M 433.43M 340.61M -151.17M
Other current liab 17.91M 23.95M 57.72M -2.04M 13.02M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -751.43M -606.69M -304.95M -354.22M -155.84M
Other liab - - - - 0.04M
Other assets - - - 1.19M 0.19M
Cash 226.65M 77.39M 170.20M 346.94M 96.12M
Total current liabilities 22.69M 28.41M 82.04M 46.61M 17.40M
Net debt -220.69M -75.41M -165.96M -340.67M -96.12M
Short term debt 1.26M 1.52M 2.26M 2.04M -
Short long term debt total 5.96M 1.98M 4.24M 6.28M -
Other stockholder equity 1056.27M 771.54M 220.72M 303.45M -3.01M
Property plant equipment - - - 2.61M 0.47M
Total current assets 323.67M 189.43M 464.67M 382.13M 101.51M
Net tangible assets - - - 340.61M -151.17M
Short term investments 90.33M 99.11M 201.16M 284.42M 45.93M
Net receivables 0.09M 0.45M 40.05M 15.31M -
Inventory - 0.00M 38.32M 9.77M -
Accounts payable 3.52M 2.94M 22.06M 46.61M 17.40M
Accumulated other comprehensive income 0.40M -0.09M 0.20M -0.09M 0.01M
Common stock total equity - - - 0.01M -
Retained earnings total equity - - - -354.22M -
Non currrent assets other 3.48M 1.47M 45.66M 1.19M 3.63M
Non current assets total 8.97M 4.20M 52.79M 9.32M 4.10M
Capital lease obligations 5.96M 1.98M 4.24M 6.28M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 14.18M 75.65M -157.05M -236.46M -46.41M
Change to liabilities - - - 1.85M 0.67M
Total cashflows from investing activities 14.04M 75.65M 92.05M -238.99M -46.41M
Net borrowings - - 0.00M - 25.90M
Total cash from financing activities 257.03M 0.35M 3.54M 431.79M 158.51M
Change to operating activities - - - 21.58M 3.92M
Net income -144.74M -301.74M 49.27M -198.38M -87.93M
Change in cash 148.80M -92.08M 107.67M 12.87M 37.31M
Begin period cash flow 78.84M 170.92M 62.53M 50.38M 13.07M
End period cash flow 227.64M 78.84M 170.20M 63.24M 50.38M
Total cash from operating activities -123.34M -167.65M 11.92M -179.87M -74.80M
Issuance of capital stock - - 231.55M 432.45M 135.00M
Depreciation 0.53M 0.90M 1.09M 0.49M 0.05M
Other cashflows from investing activities - -36.20M - - -
Change to inventory 0.00M -9.25M -73.13M -9.77M -9.77M
Change to account receivables 0.38M 39.60M -24.74M -15.31M -15.31M
Sale purchase of stock - - -3.31M 434.64M -
Other cashflows from financing activities -3.36M -1.78M -3.31M -0.66M 23.77M
Change to netincome - - - 21.71M 8.48M
Capital expenditures 0.14M 0.16M 1.24M 2.53M 0.35M
Change receivables - - - -14.82M -
Cash flows other operating - - - 21.09M -
Cash and cash equivalents changes - - - 12.93M -
Change in working capital -1.08M -45.83M -65.66M -1.64M 4.59M
Stock based compensation 27.64M 33.04M 37.16M 21.71M 3.14M
Other non cash items -5.70M 145.99M -9.94M -2.06M 5.23M
Free cash flow -123.48M -167.80M 10.68M -182.40M -75.15M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AMLX
Amylyx Pharmaceuticals Inc		 -
-%		 30.21 - 2.77 0.66 15.44 6446.63 -11.71
MKKGY
Merck KGaA ADR		 0.54
1.63%		 33.71 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.08
0.38%		 21.10 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

55 Cambridge Parkway, Cambridge, MA, United States, 02142

617 682 0917

https://amylyx.com

136

Name Title Year Born
Mr. Joshua B. Cohen Co-Founder, Co-CEO & Director 1992
Mr. Justin B. Klee Co-Founder, Co-CEO & Director 1991
Mr. James M. Frates M.B.A. Chief Financial Officer 1967
Ms. Margaret M. Olinger M.B.A Global Head of Commercial & Chief Commercial Officer 1965
Mr. Tom Holmes Chief Technical Operations Officer NA
Ms. Gina M. Mazzariello Chief Legal Officer & Gen. Counsel 1971
Ms. Shauna Horvath Head of Global Marketing NA
Ms. Debra L. Canner Global Head of HR & CHRO 1959
Dr. Patrick D. Yeramian M.D., MBA, Ph.D. Global Head of Clinical R&D and Chief Medical Officer 1959
Mr. Chris Aiello Head of Canada & GM NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…